Aquestive Therapeutics, Inc. engages in identifying, developing, and commercializing differentiated products to address unmet medical needs and solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey, and currently employs 142 full-time employees. The company went public on July 25, 2018. It is focused on developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard-of-care therapies. Aquestive has four commercialized products marketed by its licensees in the United States and worldwide and is the manufacturer of these licensed products. The company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. It is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various potential dermatological conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Follow-Up Questions
Who is the CEO of Aquestive Therapeutics Inc?
Mr. Daniel Barber is the President of Aquestive Therapeutics Inc, joining the firm since 2014.
What is the price performance of AQST stock?
The current price of AQST is $6.25, it has decreased 3.68% in the last trading day.
What are the primary business themes or industries for Aquestive Therapeutics Inc?
Aquestive Therapeutics Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Aquestive Therapeutics Inc market cap?
Aquestive Therapeutics Inc's current market cap is $753.8M
Is Aquestive Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 11 analysts have made analyst ratings for Aquestive Therapeutics Inc, including 4 strong buy, 10 buy, 1 hold, 0 sell, and 4 strong sell
